{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:26:17Z","timestamp":1793370377908,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["GM089820"],"award-info":[{"award-number":["GM089820"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005201","name":"Elsevier","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005201","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancerop\u00f4le-INCa"},{"name":"LabEx MabImprove"},{"name":"Institut Carnot CALYM"},{"DOI":"10.13039\/501100003762","name":"Institut Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004097","name":"Fondation ARC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004097","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SIRIC Montpellier Cancer","award":["INCa-DGOS-Inserm 6045"],"award-info":[{"award-number":["INCa-DGOS-Inserm 6045"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gene"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.gene.2015.04.087","type":"journal-article","created":{"date-parts":[[2015,5,14]],"date-time":"2015-05-14T03:55:11Z","timestamp":1431575711000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["IFNA2: The prototypic human alpha interferon"],"prefix":"10.1016","volume":"567","author":[{"given":"Franciane","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Uz\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gene.2015.04.087_bb0005","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.cytogfr.2014.12.006","article-title":"Twenty-five years of type I interferon-based treatment: a critical analysis of its therapeutic use","volume":"26","author":"Antonelli","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0010","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.pep.2014.04.010","article-title":"High yield soluble bacterial expression and streamlined purification of recombinant human interferon alpha-2a","volume":"99","author":"Bis","year":"2014","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.gene.2015.04.087_bb0020","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1126\/science.1224026","article-title":"Mycobacterial disease and impaired IFN-gamma immunity in humans with inherited ISG15 deficiency","volume":"337","author":"Bogunovic","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.gene.2015.04.087_bb0025","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.gene.2015.04.087_bb0030","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1158\/0008-5472.CAN-10-2820","article-title":"The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity","volume":"71","author":"Burnette","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.gene.2015.04.087_bb0035","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0969-2126(03)00120-5","article-title":"The human type I interferon receptor: NMR structure reveals the molecular basis of ligand binding","volume":"11","author":"Chill","year":"2003","journal-title":"Structure"},{"key":"10.1016\/j.gene.2015.04.087_bb0040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/eji.200324610","article-title":"Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells","volume":"34","author":"Coccia","year":"2004","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0045","first-page":"77","article-title":"Negative regulation of type I interferon signaling: facts and mechanisms","volume":"52","author":"Coccia","year":"2006","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"10.1016\/j.gene.2015.04.087_bb0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1177\/2040622314551934","article-title":"Beyond interferon: rationale and prospects for newer treatment paradigms for chronic hepatitis C","volume":"6","author":"Cortez","year":"2015","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.gene.2015.04.087_bb0055","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nri3806","article-title":"Regulation of antiviral T cell responses by type I interferons","volume":"15","author":"Crouse","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0060","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.coi.2014.10.005","article-title":"Type I interferonopathies: Mendelian type I interferon up-regulation","volume":"32C","author":"Crow","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0065","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/ni.2667","article-title":"Structural basis of a unique interferon-beta signaling axis mediated via the receptor IFNAR1","volume":"14","author":"de Weerd","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0070","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/287193a0","article-title":"Expression of human fibroblast interferon gene in Escherichia coli","volume":"287","author":"Derynck","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.gene.2015.04.087_bb0075","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1084\/jem.20101158","article-title":"Type I interferon is selectively required by dendritic cells for immune rejection of tumors","volume":"208","author":"Diamond","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0080","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1006\/geno.1994.1427","article-title":"Structure of the human type-I interferon gene cluster determined from a YAC clone contig","volume":"22","author":"Diaz","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.gene.2015.04.087_bb0085","doi-asserted-by":"crossref","first-page":"e22200","DOI":"10.1371\/journal.pone.0022200","article-title":"USP18-based negative feedback control is induced by type I and type III interferons and specifically inactivates interferon alpha response","volume":"6","author":"Francois-Newton","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.gene.2015.04.087_bb0090","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1084\/jem.20101159","article-title":"Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+dendritic cells","volume":"208","author":"Fuertes","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0095","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.cytogfr.2015.01.001","article-title":"New perspectives on type I IFNs in cancer","volume":"26","author":"Gajewski","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0100","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1038\/ncomms4016","article-title":"High efficiency cell-specific targeting of cytokine activity","volume":"5","author":"Garcin","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.gene.2015.04.087_bb0105","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.cytogfr.2009.07.005","article-title":"The role of differential expression of human interferon alpha genes in antiviral immunity","volume":"20","author":"Genin","year":"2009","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0110","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/287411a0","article-title":"Human leukocyte interferon produced by E. coli is biologically active","volume":"287","author":"Goeddel","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.gene.2015.04.087_bb0115","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJMoa053007","article-title":"Prognostic significance of autoimmunity during treatment of melanoma with interferon","volume":"354","author":"Gogas","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.immuni.2012.01.011","article-title":"Constitutive type I interferon modulates homeostatic balance through tonic signaling","volume":"36","author":"Gough","year":"2012","journal-title":"Immunity"},{"key":"10.1016\/j.gene.2015.04.087_bb0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.biochi.2007.03.005","article-title":"The antitumor effects of interferon: a personal history","volume":"89","author":"Gresser","year":"2007","journal-title":"Biochimie"},{"key":"10.1016\/j.gene.2015.04.087_bb0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.beha.2009.10.005","article-title":"Interferon in chronic myeloid leukaemia: past and future","volume":"22","author":"Guilhot","year":"2009","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.gene.2015.04.087_bb0135","first-page":"315","article-title":"Pathogenic viruses: smart manipulators of the interferon system","volume":"316","author":"Haller","year":"2007","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0140","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/intimm\/dxh318","article-title":"Regulation of the type I IFN induction: a current view","volume":"17","author":"Honda","year":"2005","journal-title":"Int. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0145","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJM198612183152503","article-title":"Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report","volume":"315","author":"Hoofnagle","year":"1986","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0150","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc. R. Soc. Lond. B Biol. Sci."},{"key":"10.1016\/j.gene.2015.04.087_bb0155","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2005-07-2709","article-title":"Specialization, kinetics, and repertoire of type 1 interferon responses by human plasmacytoid predendritic cells","volume":"107","author":"Ito","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.gene.2015.04.087_bb0160","doi-asserted-by":"crossref","first-page":"32925","DOI":"10.1074\/jbc.M806019200","article-title":"The stability of the ternary interferon-receptor complex rather than the affinity to the individual subunits dictates differential biological activities","volume":"283","author":"Kalie","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.gene.2015.04.087_bb0165","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1006\/jmbi.1997.1396","article-title":"The three-dimensional high resolution structure of human interferon alpha-2a determined by heteronuclear NMR spectroscopy in solution","volume":"274","author":"Klaus","year":"1997","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.gene.2015.04.087_bb0170","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.cyto.2011.07.019","article-title":"Binding and activity of all human alpha interferon subtypes","volume":"56","author":"Lavoie","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.gene.2015.04.087_bb0175","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1126\/science.6165082","article-title":"DNA sequence of two closely linked human leukocyte interferon genes","volume":"212","author":"Lawn","year":"1981","journal-title":"Science"},{"key":"10.1016\/j.gene.2015.04.087_bb0180","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1128\/MCB.05251-11","article-title":"Stochastic receptor expression determines cell fate upon interferon treatment","volume":"31","author":"Levin","year":"2011","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.gene.2015.04.087_bb0185","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.jmb.2007.12.005","article-title":"The EM structure of a type I interferon-receptor complex reveals a novel mechanism for cytokine signaling","volume":"377","author":"Li","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.gene.2015.04.087_bb0190","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1038\/sj.emboj.7601149","article-title":"UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity","volume":"25","author":"Malakhova","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.gene.2015.04.087_bb0195","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.gene.2015.04.087_bb0200","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1084\/jem.20111680","article-title":"Evolutionary genetic dissection of human interferons","volume":"208","author":"Manry","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0205","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group","volume":"339","author":"McHutchison","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0210","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nri3787","article-title":"Type I interferons in infectious disease","volume":"15","author":"McNab","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0215","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cell.2014.10.006","article-title":"Camouflage and misdirection: the full-on assault of ebola virus disease","volume":"159","author":"Misasi","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.gene.2015.04.087_bb0220","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/287401a0","article-title":"The structure of one of the eight or more distinct chromosomal genes for human interferon-alpha","volume":"287","author":"Nagata","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.gene.2015.04.087_bb0225","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/284316a0","article-title":"Synthesis in E. coli of a polypeptide with human leukocyte interferon activity","volume":"284","author":"Nagata","year":"1980","journal-title":"Nature"},{"key":"10.1016\/j.gene.2015.04.087_bb0230","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.0105-2896.2004.00204.x","article-title":"Interferons, interferon-like cytokines, and their receptors","volume":"202","author":"Pestka","year":"2004","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0235","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/imr.12001","article-title":"Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation","volume":"250","author":"Piehler","year":"2012","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0240","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0245","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0250","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.4049\/jimmunol.0903374","article-title":"Intron-containing type I and type III IFN coexist in amphibians: refuting the concept that a retroposition event gave rise to type I IFNs","volume":"184","author":"Qi","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0255","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1110\/ps.062283006","article-title":"Determination of the human type I interferon receptor binding site on human interferon-alpha2 by cross saturation and an NMR-based model of the complex","volume":"15","author":"Quadt-Akabayov","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.gene.2015.04.087_bb0260","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0969-2126(96)00152-9","article-title":"Zinc mediated dimer of human interferon-alpha 2b revealed by X-ray crystallography","volume":"4","author":"Radhakrishnan","year":"1996","journal-title":"Structure"},{"key":"10.1016\/j.gene.2015.04.087_bb0265","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cytogfr.2014.10.002","article-title":"Role of type I interferon in inducing a protective immune response: perspectives for clinical applications","volume":"26","author":"Rizza","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0270","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.gene.2015.04.087_bb0275","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1158\/0008-5472.CAN-10-2788","article-title":"Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis","volume":"71","author":"Schiavoni","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.gene.2015.04.087_bb0280","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.coviro.2011.10.008","article-title":"Interferon-stimulated genes and their antiviral effector functions","volume":"1","author":"Schoggins","year":"2011","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.gene.2015.04.087_bb0285","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nature04606","article-title":"CD69 acts downstream of interferon-alpha\/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs","volume":"440","author":"Shiow","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.gene.2015.04.087_bb0290","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s11096-005-1319-7","article-title":"Side effects of interferon-alpha therapy","volume":"27","author":"Sleijfer","year":"2005","journal-title":"Pharm. World Sci."},{"key":"10.1016\/j.gene.2015.04.087_bb0295","doi-asserted-by":"crossref","first-page":"7142","DOI":"10.1073\/pnas.1016569108","article-title":"Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy","volume":"108","author":"Stagg","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2015.04.087_bb0300","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.4049\/jimmunol.1402794","article-title":"Interfering with immunity: detrimental role of type I IFNs during infection","volume":"194","author":"Stifter","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0305","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.6158094","article-title":"At least three human type alpha interferons: structure of alpha 2","volume":"209","author":"Streuli","year":"1980","journal-title":"Science"},{"key":"10.1016\/j.gene.2015.04.087_bb0310","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jmb.2008.01.017","article-title":"Ligand binding induces a conformational change in ifnar1 that is propagated to its membrane-proximal domain","volume":"377","author":"Strunk","year":"2008","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.gene.2015.04.087_bb0315","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood.V69.5.1280.1280","article-title":"Clinical investigation of human alpha interferon in chronic myelogenous leukemia","volume":"69","author":"Talpaz","year":"1987","journal-title":"Blood"},{"key":"10.1016\/j.gene.2015.04.087_bb0320","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/leu.2012.313","article-title":"Re-emergence of interferon-alpha in the treatment of chronic myeloid leukemia","volume":"27","author":"Talpaz","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.gene.2015.04.087_bb0325","doi-asserted-by":"crossref","first-page":"5230","DOI":"10.1073\/pnas.77.9.5230","article-title":"Expression of the human fibroblast interferon gene in Escherichia coli","volume":"77","author":"Taniguchi","year":"1980","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.gene.2015.04.087_bb0330","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cell.2011.06.048","article-title":"Structural linkage between ligand discrimination and receptor activation by type I interferons","volume":"146","author":"Thomas","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.gene.2015.04.087_bb0335","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3389\/fimmu.2014.00526","article-title":"Harnessing mechanistic knowledge on beneficial versus deleterious IFN-I effects to design innovative immunotherapies targeting cytokine activity to specific cell types","volume":"5","author":"Tomasello","year":"2014","journal-title":"Front. Immunol."},{"key":"10.1016\/j.gene.2015.04.087_bb0340","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1084\/jem.20101664","article-title":"Type I interferon: friend or foe?","volume":"207","author":"Trinchieri","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0345","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.cytogfr.2014.10.006","article-title":"High efficiency targeting of IFN-alpha activity: possible applications in fighting tumours and infections","volume":"26","author":"Uze","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.gene.2015.04.087_bb0350","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1432-1033.1990.tb15570.x","article-title":"Three human interferon-alpha 2 subvariants disclose structural and functional differences","volume":"190","author":"von Gabain","year":"1990","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.gene.2015.04.087_bb0355","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.201412049","article-title":"Receptor dimerization dynamics as regulatory valve for plasticity of type I interferon signaling","author":"Wilmes","year":"2015","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.gene.2015.04.087_bb0360","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.gene.2007.03.018","article-title":"Evolution of the interferon alpha gene family in Eutherian mammals","volume":"397","author":"Woelk","year":"2007","journal-title":"Gene"},{"key":"10.1016\/j.gene.2015.04.087_bb0365","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1182\/blood-2007-12-125906","article-title":"Interferon-alpha 2b-induced thrombocytopenia is caused by inhibition of platelet production but not proliferation and endomitosis in human megakaryocytes","volume":"112","author":"Yamane","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.gene.2015.04.087_bb0370","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1056\/NEJM200012073432301","article-title":"Peginterferon alfa-2a in patients with chronic hepatitis C","volume":"343","author":"Zeuzem","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.gene.2015.04.087_bb0375","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nature13801","article-title":"Human intracellular ISG15 prevents interferon-alpha\/beta over-amplification and auto-inflammation","volume":"517","author":"Zhang","year":"2015","journal-title":"Nature"}],"container-title":["Gene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915005727?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378111915005727?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T04:54:11Z","timestamp":1599022451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378111915005727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":75,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S0378111915005727"],"URL":"https:\/\/doi.org\/10.1016\/j.gene.2015.04.087","relation":{},"ISSN":["0378-1119"],"issn-type":[{"value":"0378-1119","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFNA2: The prototypic human alpha interferon","name":"articletitle","label":"Article Title"},{"value":"Gene","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gene.2015.04.087","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}